Products with Inhibitors bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4804 | Deguelin |
| 1. Deguelin has anti-cancer activity, such as anti osteosarcoma, lung cancer; via inducing the apoptosis of cancer cells through a ROS driven Akt pathway, EPC suppression by FAK-integrin-ILK-dependent actin remodeling . 2. Deguelin possesses antitumor effect by targeting Akt in dual axis such as EGFR and IGF1R signaling pathways and suggests that it provides an applicable therapeutic strategy for HNSCC patients. 3. Deguelin is a potent in vitro inhibitor of the mutant form of NPM1, which provides the molecular basis for its anti-leukemia activities in NPM1 mutant acute myeloid leukemia cells. | |
| BCN4805 | 6,8-Diprenylgenistein |
| 1. 6,8-Diprenylgenistein has antimicrobial activity . 2. 6,8-Diprenylgenistein has anti-bacteria activity against Gram-negative and Gram-positive bacteria. | |
| BCN4815 | (-)-Variabilin |
| 1. Variabilin, a novel inhibitor of human platelet aggregation, it is a potent RGD (Arg-Gly-Asp)-containing antagonist of the fibrinogen receptor glycoprotein IIb-IIIa (GPIIb-IIIa; αIIbβ3) and the vitronectin receptor αvβ3. 2. Variabilin is an inhibitor of human secretory and cytosolic phospholipase A2 (PLA2) activities that controls eicosanoid production in vitro and in vivo, inhibits neutrophil degranulation and superoxide generation in vitro and shows anti-inflammatory activity after topical or p.o. administration to mice. 3. Variabilin is an antimicrobial furanosesterterpene. 4. Variabilin is an important chemotaxonomic marker for the family Irciniidae. | |
| BCN4828 | Erythrabyssin II |
| 1. Erythrabyssin II actives against several strains of Staphylococcus and Streptococcus with an MIC range of 0.78-1.56 microg/ml. 2. Erythrabyssin II inhibits bacterial neuraminidase in a dose-dependent manner with significant inhibition (IC(50)=0.09-3.25 μM). | |
| BCN4846 | Sanggenon N |
| 1. Sanggenon N shows protective effects on t-BHP-induced oxidative stress with the EC50 value of 23.45 ± 4.72 uM. 2. Sanggenon N inhibits lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophages. | |
